Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer
about
Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate CancerRadiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.Stereotactic radiotherapy of the prostate: fractionation and utilization in the United States.Cardiac avoidance in breast radiotherapy: many choices for a worthwhile objective.High-dose-rate brachytherapy boost for prostate cancer: rationale and techniqueClinical management and burden of prostate cancer: a Markov Monte Carlo model.After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancerComparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer.Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts.Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason ScoreHypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study.Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.Comment on "Medical use of all high activity sources should be eliminated for security concerns" [Med. Phys. 42, 6773-6775 (2015)].Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials.Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer.PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol.Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial.The potential failure risk of the cone-beam computed tomography-based planning target volume margin definition for prostate image-guided radiotherapy based on a prospective single-institutional hybrid analysis.Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.High dose-rate brachytherapy in the treatment of prostate cancerHigh-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
P2860
Q33819775-63886030-B129-4D98-9ADD-F4DA78819000Q33918003-FA06BCB7-13C0-49AB-8B78-ED0587A35C91Q33919686-9EB2F49A-0056-41C3-A12A-B98DB01D98D6Q34297359-E7847EAD-A79F-4F97-9DB6-BC8CADE3912DQ34355194-BA829C1A-77FD-416E-9F49-CEB71D5CA6A1Q34634410-FEE31D73-2C76-4AD2-B89E-080EED5C62B5Q36007746-B9F5E6E6-BF62-4F3F-898A-18FB5B26E8B0Q36276830-C28FBDDA-EBB2-43DD-B412-A30B23D284C5Q36471873-04265ECA-F925-4434-B3BC-8B6353F70804Q36690539-823E6DF9-80CF-449F-A9E8-79FCAA857BCBQ37213040-DA2602A5-4595-4104-9CA8-353333DD3218Q39456165-6F662512-0980-40B0-820D-593F1E5A59EDQ41284066-28E3C5C5-1CD9-4AC3-9621-8F3AB8B736E3Q41541990-728644AE-01BB-46BE-9B58-53AF04865866Q46088597-D30BB0CF-E81C-417D-B4DB-2A54C8EAADC8Q46969507-FBA25BC2-0E8D-45CA-8D1F-8A2FDE8DAC11Q48543708-DB95BF3A-1E06-4CD4-B488-E75BD282B2B3Q55054493-ED940226-DAAB-4F1D-8AF8-D6312E439632Q55233411-2F535B26-FD39-4A49-B447-F9520F26A38FQ55261881-4346F1EE-F555-49A3-AE3D-667494CCFE0BQ55479788-8AE3E866-01FB-4B66-B485-2C3483CC13D1Q55665448-A55BDFD0-885A-4255-A48E-F80ACF4F6878Q57112470-641A5CD7-0E9B-4F35-AF78-9832E6FF094BQ58753445-5AD20C7D-BD50-483E-BA42-B5B561CBE2A6
P2860
Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer
description
article
@en
im Januar 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2014
@uk
name
Comparison of high-dose (86.4 ...... ermediate-risk prostate cancer
@en
Comparison of high-dose
@nl
type
label
Comparison of high-dose (86.4 ...... ermediate-risk prostate cancer
@en
Comparison of high-dose
@nl
prefLabel
Comparison of high-dose (86.4 ...... ermediate-risk prostate cancer
@en
Comparison of high-dose
@nl
P2093
P2860
P50
P356
P1433
P1476
Comparison of high-dose (86.4 ...... ermediate-risk prostate cancer
@en
P2093
Marisa A Kollmeier
Pirus Ghadjar
William Polkinghorn
Yoshiya Yamada
Zachary S Zumsteg
P2860
P304
P356
10.1111/BJU.12514
P577
2014-01-22T00:00:00Z